AstraZeneca Boosts Cancer Therapies with $1B EsoBiotec Buy
Details : Through the acquisition, AstraZeneca will leverage EsoBiotec ENaBL platform and their products including ESO-T01. It is being evaluated for r/r Multiple Myeloma.
Product Name : ESO-T01
Product Type : Cell and Gene therapy
Upfront Cash : $1,000.0 million
March 17, 2025
EsoBiotec Doses First Patient in BCMA CAR-T ESO-T01 Trial for Multiple Myeloma
Details : ESO-T01 is an immune shielded lentiviral vector that reprograms T lymphocytes in vivo into highly effective BCMA CAR-T cells, for the treatment of r/r multiple myeloma.
Product Name : ESO-T01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 08, 2025
EsoBiotec Begins Clinical Trial of BCMA CAR-T Candidate ESO-T01 for Multiple Myeloma
Details : ESO-T01 is an immune shielded lentiviral vector that reprograms T lymphocytes in vivo into highly effective BCMA CAR-T cells, for the treatment of multiple myeloma.
Product Name : ESO-T01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 11, 2024
Galapagos Receives FDA Clearance for ATALANTA-1 CD19 CAR-T Study in NHL
Details : GLPG5101 is an IV infused, second generation anti-CD19/4-1BB CAR-T product candidate. Currently being assessed in patients with relapsed/refractory non-Hodgkin lymphoma.
Product Name : GLPG5101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 23, 2024
Lead Product(s) : CYAD-101,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Celyad Oncology Announces Voluntary Pause of CYAD-101-002 Phase 1b Trial
Details : The trial is evaluating TCR Inhibitory Molecule-based allogeneic NKG2D CAR T cell investigational therapy CYAD-101 administered concurrently with FOLFOX chemotherapy, followed by MSD’s anti-PD-1 therapy, KEYTRUDA®, in patients with refractory metastat...
Product Name : CYAD-101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 28, 2022
Lead Product(s) : CYAD-101,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CYAD-101,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b Trial
Details : Company announced clinical hold on CYAD-101-002 Phase 1b trial for CYAD-101, TCR Inhibitory Molecule based allogeneic NKG2D CAR T cell investigational therapy for treatment of advanced mCRC, due to insufficient information to assess risk to study subject...
Product Name : CYAD-101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 03, 2022
Lead Product(s) : CYAD-101,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CYAD-101,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial
Details : CYAD-101 is an investigational, non-gene edited allogeneic CAR T engineered to co-express chimeric antigen receptor based on NKG2D, that binds to eight stress-induced ligands expressed by a broad range of tumor cells and the novel inhibitory peptide TIM.
Product Name : CYAD-101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 08, 2022
Lead Product(s) : CYAD-101,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CYAD-101,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Fortress Investment Group
Deal Size : $32.5 million
Deal Type : Private Placement
Celyad Oncology Announces $32.5 Million Private Placement with Fortress Investment Group
Details : The Company intends to use net proceeds from the private placement to fund research and development expenses, including the clinical development of its allogeneic CAR T candidates CYAD-101 and CYAD-211, to advance the current pipeline of preclinical CAR ...
Product Name : CYAD-101
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 12, 2021
Lead Product(s) : CYAD-101,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Fortress Investment Group
Deal Size : $32.5 million
Deal Type : Private Placement
Lead Product(s) : CYAD-101,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The recommended dose of 1×109 CYAD-101 cells per infusion will be further evaluated in the expansion cohort of the alloSHRINK trial concurrently with FOLFIRI chemotherapy.
Product Name : CYAD-101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 18, 2021
Lead Product(s) : CYAD-101,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CYAD-211,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The presentations will focus on the company’s anti-BCMA allogeneic CAR T candidate, CYAD-211, and autologous NKG2D receptor-based CAR T candidates CYAD-01 and CYAD-02.
Product Name : CYAD-211
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 11, 2020
Lead Product(s) : CYAD-211,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable